Potential approaches for heterologous prion protein treatment of prion diseases

REFERENCES

• Valleron AJ, Boelle PY, Will R, Cesbron JY. Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom. Science 2001; 294:1726-8; PMID:11721058; http://dx.doi.org/10.1126/science.1066838
   PubMed Web of Science ®Google Scholar
• Hetz C, Maundrell K, Soto C. Is loss of function of the prion protein the cause of prion disorders? Trends Mol Med 2003; 9:237-43; PMID:12829011; http://dx.doi.org/10.1016/S1471-4914(03)00069-8
   PubMed Web of Science ®Google Scholar
• Caughey B, Chesebro B. Transmissible spongiform encephalopathies and prion protein interconversions. Adv Virus Res 2001; 56:277-311; PMID:11450303; http://dx.doi.org/10.1016/S0065-3527(01)56031-5
   PubMed Web of Science ®Google Scholar
• Prusiner SB, Scott M, Foster D, Pan KM, Groth D, Mirenda C, Torchia M, Yang SL, Serban D, Carlson GA, et al. Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell 1990; 63:673-86; PMID:1977523; http://dx.doi.org/10.1016/0092-8674(90)90134-Z
   PubMed Web of Science ®Google Scholar
• Mallik S, Yang W, Norstrom EM, Mastrianni JA. Live cell fluorescence resonance energy transfer predicts an altered molecular association of heterologous PrPSc with PrPC. J Biol Chem 285:8967-75; PMID:20086009; http://dx.doi.org/10.1074/jbc.M109.058107
   PubMed Web of Science ®Google Scholar
• Bett C, Fernandez-Borges N, Kurt TD, Lucero M, Nilsson KP, Castilla J, Sigurdson CJ. Structure of the beta2-alpha2 loop and interspecies prion transmission. FASEB J 26:2868-76; PMID:22490928; http://dx.doi.org/10.1096/fj.11-200923
   PubMed Web of Science ®Google Scholar
• Giachin G, Biljan I, Ilc G, Plavec J, Legname G. Probing early misfolding events in prion protein mutants by NMR spectroscopy. Molecules 18:9451-76; PMID:23966072; http://dx.doi.org/10.3390/molecules18089451
   PubMed Web of Science ®Google Scholar
• Singh J, Udgaonkar JB. Structural effects of multiple pathogenic mutations suggest a model for the initiation of misfolding of the prion protein. Angew Chem Int Ed Engl 54:7529-33; PMID:25959220; http://dx.doi.org/10.1002/anie.201501011
   PubMed Web of Science ®Google Scholar
• Liemann S, Glockshuber R. Influence of amino acid substitutions related to inherited human prion diseases on the thermodynamic stability of the cellular prion protein. Biochemistry 1999 38:3258-67; PMID:10079068; http://dx.doi.org/10.1021/bi982714g
   PubMed Web of Science ®Google Scholar
• Apetri AC, Surewicz K, Surewicz WK. The effect of disease-associated mutations on the folding pathway of human prion protein. J Biol Chem 2004; 279:18008-14; PMID:14761942; http://dx.doi.org/10.1074/jbc.M313581200
   PubMed Web of Science ®Google Scholar
• Singh J, Udgaonkar JB. Molecular Mechanism of the Misfolding and Oligomerization of the Prion Protein: Current Understanding and Its Implications. Biochemistry 54:4431-42; PMID:26171558; http://dx.doi.org/10.1021/acs.biochem.5b00605
   PubMed Web of Science ®Google Scholar
• Heppner FL, Musahl C, Arrighi I, Klein MA, Rulicke T, Oesch B, Zinkernagel RM, Kalinke U, Aguzzi A. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 2001; 294:178-82; PMID:11546838; http://dx.doi.org/10.1126/science.1063093
   PubMed Web of Science ®Google Scholar
• White AR, Enever P, Tayebi M, Mushens R, Linehan J, Brandner S, Anstee D, Collinge J, Hawke S. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003; 422:80-3; PMID:12621436; http://dx.doi.org/10.1038/nature01457
   PubMed Web of Science ®Google Scholar
• Horiuchi M, Priola SA, Chabry J, Caughey B. Interactions between heterologous forms of prion protein: binding, inhibition of conversion, and species barriers. Proc Natl Acad Sci U S A 2000; 97:5836-41; PMID: 10811921; http://dx.doi.org/10.1073/pnas.110523897
   PubMed Web of Science ®Google Scholar
• Priola SA, Caughey B, Race RE, Chesebro B. Heterologous PrP molecules interfere with accumulation of protease-resistant PrP in scrapie-infected murine neuroblastoma cells. J Virol 1994; 68:4873-8; PMID:7913509
   PubMed Web of Science ®Google Scholar
• Vorberg I, Groschup MH, Pfaff E, Priola SA. Multiple amino acid residues within the rabbit prion protein inhibit formation of its abnormal isoform. J Virol 2003; 77:2003-9; PMID:12525634; http://dx.doi.org/10.1128/JVI.77.3.2003-2009.2003
   PubMed Web of Science ®Google Scholar
• Skinner PJ, Kim HO, Bryant D, Kinzel NJ, Reilly C, Priola SA, Ward AE, Goodman PA, Olson K, Seelig DM. Treatment of Prion Disease with Heterologous Prion Proteins. PLoS One 10:e013; 1993.
   Google Scholar
• Gibbs CJ, Jr., Gajdusek DC. Experimental subacute spongiform virus encephalopathies in primates and other laboratory animals. Science 1973; 182:67-8; PMID:4199733; http://dx.doi.org/10.1126/science.182.4107.67
   PubMed Web of Science ®Google Scholar
• Barlow RM, Rennie JC. The fate of ME7 scrapie infection in rats, guinea-pigs and rabbits. Res Vet Sci 1976; 21:110-1; PMID:821118
   PubMed Web of Science ®Google Scholar
• Chianini F, Fernandez-Borges N, Vidal E, Gibbard L, Pintado B, de Castro J, Priola SA, Hamilton S, Eaton SL, Finlayson J, et al. Rabbits are not resistant to prion infection. Proc Natl Acad Sci U S A 109:5080-5; PMID:22416127; http://dx.doi.org/10.1073/pnas.1120076109
   PubMed Web of Science ®Google Scholar
• Vidal E, Fernandez-Borges N, Pintado B, Ordonez M, Marquez M, Fondevila D, Torres JM, Pumarola M, Castilla J. Bovine spongiform encephalopathy induces misfolding of alleged prion-resistant species cellular prion protein without altering its pathobiological features. J Neurosci 33:7778-86; PMID:23637170; http://dx.doi.org/10.1523/JNEUROSCI.0244-13.2013
   PubMed Web of Science ®Google Scholar
• Huang XQ, Hardison RC, Miller W. A space-efficient algorithm for local similarities. Comput Appl Biosci 1990; 6:373-81; PMID:2257499
   PubMedGoogle Scholar
• Begley DJ. Transport of prion proteins across the blood-brain barrier. Exp Neurol 2009; 220:217-8; PMID:19682986; http://dx.doi.org/10.1016/j.expneurol.2009.08.006
   PubMed Web of Science ®Google Scholar
• Chabry J, Caughey B, Chesebro B. Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J Biol Chem 1998; 273:13203-7; PMID:9582363; http://dx.doi.org/10.1074/jbc.273.21.13203
   PubMed Web of Science ®Google Scholar
• Chabry J, Priola SA, Wehrly K, Nishio J, Hope J, Chesebro B. Species-independent inhibition of abnormal prion protein (PrP) formation by a peptide containing a conserved PrP sequence. J Virol 1999; 73:6245-50; PMID:10400714
   PubMed Web of Science ®Google Scholar
• Mallucci GR, Ratte S, Asante EA, Linehan J, Gowland I, Jefferys JG, Collinge J. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J 2002; 21:202-10; PMID:11823413; http://dx.doi.org/10.1093/emboj/21.3.202
   PubMed Web of Science ®Google Scholar
• White MD, Farmer M, Mirabile I, Brandner S, Collinge J, Mallucci GR. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci U S A 2008; 105:10238-43; PMID:18632556; http://dx.doi.org/10.1073/pnas.0802759105
   PubMed Web of Science ®Google Scholar
• Toupet K, Compan V, Crozet C, Mourton-Gilles C, Mestre-Frances N, Ibos F, Corbeau P, Verdier JM, Perrier V. Effective gene therapy in a mouse model of prion diseases. PLoS One 2008; 3:e2773; http://dx.doi.org/10.1371/journal.pone.0002773
   PubMed Web of Science ®Google Scholar